News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Oscar Escobar-Vidarte, MD

Articles by Oscar Escobar-Vidarte, MD

Signaling Pathways in the Relapse of Glioblastoma

Signaling Pathways in the Relapse of Glioblastoma

ByJavier Orozco-Mera, MD, FACS, MSc,Fernando Peralta-Pizza, MD,Oscar Escobar-Vidarte, MD,Brenda Coll-Tello, MSc,Aurelio Ariza, MD

March 23rd 2023

Javier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Latest Updated Articles

Signaling Pathways in the Relapse of Glioblastoma
March 23rd 2023

Trending on CancerNetwork

FDA Approves Ruxolitinib Tablets for Hematologic Malignancies

Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer

Precision Medicine and the “Slow Death” of Transplant in Lymphoma

135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study

TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study